Title : KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.

Pub. Date : 2017 May

PMID : 28407465






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based treatment. gemcitabine KRAS proto-oncogene, GTPase Homo sapiens